Stockscreener 앱 받기
4.42
4.99%
0.21
시간 외 거래:
4.42
전일 마감가:
$4.21
열려 있는:
$4.3
하루 거래량:
596.23K
Relative Volume:
0.51
시가총액:
$145.91M
수익:
$59.63M
순이익/손실:
$-72.21M
주가수익비율:
-2.1048
EPS:
-2.1
순현금흐름:
$-30.85M
1주 성능:
+16.01%
1개월 성능:
+7.54%
6개월 성능:
+27.38%
1년 성능:
-27.18%
1일 변동 폭
$4.10
$4.535
1주일 범위
$3.58
$4.535
52주 변동 폭
$1.81
$7.4802
908 디바이시스 Stock (MASS) Company Profile
명칭
908 Devices Inc
전화
978-729-4478
주소
645 SUMMER STREET, BOSTON
MASS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MASS
908 Devices Inc
|
4.42 | 145.91M | 59.63M | -72.21M | -30.85M | -2.10 |
|
ABT
Abbott Laboratories
|
127.96 | 221.98B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
94.27 | 139.04B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
353.42 | 134.44B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
84.22 | 107.20B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
69.87 | 40.65B | 5.72B | 4.17B | 259.90M | 6.97 |
908 디바이시스 Stock (MASS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-13 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2023-02-07 | 개시 | Stephens | Overweight |
| 2021-10-15 | 재개 | Cowen | Outperform |
| 2021-01-12 | 개시 | Cowen | Outperform |
| 2021-01-12 | 개시 | SVB Leerink | Outperform |
| 2021-01-12 | 개시 | Stifel | Buy |
| 2021-01-12 | 개시 | William Blair | Outperform |
모두보기
908 디바이시스 주식(MASS)의 최신 뉴스
Prudential Financial Inc. Makes New Investment in 908 Devices Inc. (NASDAQ:MASS) - Defense World
908 Devices Leads These 3 Penny Stocks To Consider - Yahoo Finance
908 Devices (NASDAQ:MASS) Earns Sell (D-) Rating from Weiss Ratings - Defense World
The Zacks Analyst Blog Highlights Fidelity NASDAQ Composite Index ETF, ThredUp, 908 Devices, Logility Supply Chain, Palomar and EZCORP - Nasdaq
Charles Schwab Investment Management Inc. Has $444,000 Stake in 908 Devices Inc. (NASDAQ:MASS) - Defense World
908 Devices (NASDAQ:MASS) Given Sell (E+) Rating at Weiss Ratings - Defense World
Q1 Earnings Estimate for 908 Devices Issued By William Blair - Defense World
Best Momentum Stocks to Buy for March 13th - Yahoo Finance
908 Devices (MASS) Stock Jumps on Strength of New Order Announcement - Stocks Telegraph
908 Devices gets $1.7M order from Ministry of Health of Ukraine - MSN
908 Devices Receives $1.7M Order from the Ministry of Health of Ukraine for its Handheld Mass Spec Device - 01net
908 Devices climbs on $1.7 mln order from Ukraine - TradingView
908 Devices secures $1.7 million order from Ukraine - Investing.com India
908 Devices secures $1.7 million order from Ukraine By Investing.com - Investing.com South Africa
908 Devices Receives $1.7M Order From The Ministry Of Health Of Ukraine For Its Handheld Mass Spec Device - Marketscreener.com
What Is The Outlook For 908 Devices Inc (NASDAQ: MASS) Like For Short-Term? - Stocks Register
908 Devices: Strategic Divestiture and Strong Financial Performance Drive Buy Rating - TipRanks
Repligen Corporation’s Acquisition of Bioprocessing PAT Device Portfolio from 908 Devices - Global Legal Chronicle
Weiss Ratings Reaffirms Sell (E+) Rating for 908 Devices (NASDAQ:MASS) - Defense World
908 Devices Inc. (MASS) Reports Q4 Loss, Tops Revenue Estimates - MSN
908 Devices Inc. SEC 10-K Report - TradingView
Repligen buying 908 Devices’ Bioprocess Analytics portfolio - BioWorld Online
908 Devices Makes Key Divestiture (Rating Upgrade) (NASDAQ:MASS) - Seeking Alpha
908 Devices earnings missed by $0.33, revenue fell short of estimates - Investing.com Australia
Stifel maintains Buy on 908 Devices, target steady at $6 By Investing.com - Investing.com Canada
Stifel maintains Buy on 908 Devices, target steady at $6 - Investing.com India
908 Devices Inc. Reports Strategic Transformation and Growth - MSN
Repligen lays down $70m to buy analytics tech from 908 Devices - BioProcess Insider
Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices - Genetic Engineering & Biotechnology News
908 Devices Inc.'s (NASDAQ:MASS) 55% Jump Shows Its Popularity With Investors - Simply Wall St
908 Devices Inc (MASS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amid Strategic ... - Yahoo Finance
908 Devices stock surges on strategic transformation and growth outlook By Investing.com - Investing.com South Africa
908 Devices stock surges on strategic transformation and growth outlook - Investing.com
Repligen Corporation acquired the assets related to bioprocessing analytics portfolio of 908 Devices Inc. for $56 million. - Marketscreener.com
908 Devices jumps as Repligen buys bioprocessing analytics portfolio - MSN
Earnings call transcript: 908 Devices Q4 2024 revenue up 31%, stock surges - Investing.com India
MASS’s 2023 Market Dance: Up 66.78% – Time to Invest? - The InvestChronicle
908 Devices Strategic Shift: Desktop Sale To Repligen Optimizes Future Growth - Benzinga
Strategic Divestment and Focus on Growth Propel 908 Devices to a Buy Rating - TipRanks
908 Devices reports Q4 EPS (56c), consensus (35c) - TipRanks
908 Devices Inc. reports results for the quarter ended December 31Earnings Summary - TradingView
Repligen Corporation acquired Bioprocessing Analytics Portfolio from 908 Devices Inc. for $70 million. - Marketscreener.com
Repligen’s Strategic Acquisition of 908 Devices’ Bioprocessing Assets Boosts Buy Rating - TipRanks
MASSive Gains for 908 Devices: Is This Stock Turning Around? - RagingBull
908 Devices Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024 - Marketscreener.com
Investor presentation (03/04/2025 00: 00 - Marketscreener.com
Repligen Acquires 908 Devices’ Bioprocess Analytics Portfolio - Contract Pharma
908 디바이시스 (MASS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
908 디바이시스 주식 (MASS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Turner Michael S. | Chief Legal & Admin Officer |
Feb 03 '25 |
Sale |
2.33 |
9,672 |
22,499 |
24,603 |
| Knopp Kevin J. | President and CEO |
Feb 03 '25 |
Sale |
2.32 |
16,001 |
37,109 |
692,733 |
| Brown Christopher D. | Chief Product Officer |
Feb 03 '25 |
Sale |
2.34 |
7,767 |
18,191 |
962,122 |
| Brown Christopher D. | Chief Product Officer |
Dec 19 '24 |
Option Exercise |
1.58 |
55,131 |
87,107 |
946,453 |
| Knopp Kevin J. | President and CEO |
Dec 13 '24 |
Option Exercise |
1.63 |
158,044 |
257,771 |
667,025 |
| Brown Christopher D. | Chief Product Officer |
Aug 07 '24 |
Option Exercise |
1.58 |
6,328 |
9,998 |
891,322 |
| Eisenberg Marcia | Director |
Jun 07 '24 |
Option Exercise |
0.00 |
682 |
0 |
6,816 |
| Knopp Kevin J. | President and CEO |
May 13 '24 |
Buy |
6.42 |
10,000 |
64,200 |
508,981 |
| Knopp Kevin J. | President and CEO |
May 10 '24 |
Buy |
5.77 |
10,000 |
57,700 |
498,981 |
| Knopp Kevin J. | President and CEO |
May 09 '24 |
Buy |
5.83 |
10,000 |
58,300 |
488,981 |
0.37%
1.32%
자본화:
|
볼륨(24시간):